Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Strong Sell at Zacks Investment Research


Share on StockTwits

Seres Therapeutics (NASDAQ:MCRB) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other research firms have also recently commented on MCRB. BidaskClub raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 9th. JMP Securities assumed coverage on shares of Seres Therapeutics in a report on Wednesday, December 23rd. They issued a “market perform” rating for the company. ValuEngine cut shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 1st. Piper Sandler upped their price objective on Seres Therapeutics from $40.00 to $49.00 and gave the company an “overweight” rating in a research note on Monday, November 9th. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Monday, November 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $33.07.

MCRB stock opened at $25.86 on Tuesday. The stock has a market capitalization of $2.36 billion, a P/E ratio of -22.10 and a beta of 4.14. The company has a current ratio of 6.73, a quick ratio of 6.73 and a debt-to-equity ratio of 0.13. Seres Therapeutics has a 12 month low of $2.52 and a 12 month high of $38.50. The firm has a 50-day moving average price of $25.62 and a 200-day moving average price of $22.69.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Monday, November 9th. The biotechnology company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.12). The company had revenue of $1.42 million during the quarter, compared to the consensus estimate of $9.15 million. Seres Therapeutics had a negative return on equity of 2,867.98% and a negative net margin of 385.22%. As a group, equities analysts predict that Seres Therapeutics will post -1 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. HM Payson & Co. acquired a new stake in Seres Therapeutics during the 3rd quarter valued at approximately $28,000. BNC Wealth Management LLC acquired a new stake in Seres Therapeutics during the 3rd quarter valued at approximately $38,000. Meeder Asset Management Inc. increased its position in Seres Therapeutics by 225.6% during the 3rd quarter. Meeder Asset Management Inc. now owns 2,641 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 1,830 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Seres Therapeutics by 186.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,840 shares of the biotechnology company’s stock worth $80,000 after buying an additional 1,850 shares in the last quarter. Finally, Strs Ohio boosted its holdings in shares of Seres Therapeutics by 1,080.0% during the 3rd quarter. Strs Ohio now owns 5,900 shares of the biotechnology company’s stock worth $167,000 after buying an additional 5,400 shares in the last quarter. 75.37% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI).

Further Reading: How to track put option volume

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.